Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban (INSIST-IT2): a Prospective, Randomized, Double Blinded, Multi-center Study

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

It remains uncertain whether intravenous tirofiban administered before endovascular thrombectomy could improve disability severity for patients with LVO due to intracranial atherosclerosis.The current study aimed to assess the efficacy and safety of administering intravenous tirofiban before endovascular thrombectomy for improving clinical outcomes in patients with anterior circulation LVO due to intracranial atherosclerosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years;

• Anterior circulation large vessel occlusion (the internal carotid artery or the first or second segment of the middle cerebral artery) confirmed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA);

• Eligible for endovascular treatment within 12 hours of symptom onset;

• Based on the patient's medical history, clinical presentation, and imaging findings, large artery atherosclerosis is highly suspected as the underlying etiology;

• Baseline National Institute of Health Stroke Scale (NIHSS) ≥ 6;

• Baseline ASPECTS ≥ 6 on CT;

• A pre-stroke modified Rankin Scale (mRS) score of ≤2;

• Signed informed consent by patient or their legally authorized representative.

Locations
Other Locations
China
General Hospital of Northern Theater Command
RECRUITING
Shenyang
Contact Information
Primary
Hui-Sheng Chen
chszh@aliyun.com
+86-024-28897511
Time Frame
Start Date: 2025-11-13
Estimated Completion Date: 2027-12-30
Participants
Target number of participants: 870
Treatments
Experimental: Tirofiban group
Intravenous tirofiban before endovascular thrombectomy
Placebo_comparator: Placebo group
Intravenous placebo before Endovascular Thrombectomy
Related Therapeutic Areas
Sponsors
Leads: General Hospital of Shenyang Military Region

This content was sourced from clinicaltrials.gov

Similar Clinical Trials